Enadoline, a selective kappa opioid agonist: comparison with butorphanol and hydromorphone in humans
The DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.
Abstract
Rationale The availability of the highly selective and specific kappa opioid agonist enadoline provides an opportunity to explore the function of kappa receptors in humans and their potential utility as a target for substance abuse pharmacotherapy development.Objectives The purpose of this study was to characterize the pharmacodynamic effects of enadoline, a selective kappa agonist, and to compare it with butorphanol, a mixed mu/kappa agonist, and hydromorphone, a mu agonist, in humans.Methods Pilot evaluation (n=3) served to establish intramuscular doses of enadoline (20, 40, 80, and 160 microg/70 kg), butorphanol (1.5, 3, 6, and 12 mg/70 kg), and hydromorphone (1.5, 3, and 6 mg/70 kg) of comparable activity. These acute doses were examined under double-blind, placebo-controlled and constrained randomized conditions with a minimum of 72 h between tests in volunteers with polysubstance abuse histories (n=6). Physiological and subject- and observer-rated measures were collected 30 min before and for 4 h after administration.Results Enadoline significantly increased measures of sedation, confusion and dizziness, produced visual distortions and feelings of depersonalization, and increased urinary output. The highest dose (160 microg/70 kg) was not tolerated and led to psychotomimetic effects. Hydromorphone produced prototypic mu opioid effects including respiratory depression, miosis, and euphoria. Butorphanol was most similar to hydromorphone and shared few effects with enadoline.Conclusions These results are discussed with respect to the potential use and safety of kappa agonists for clinical indications.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“A kappa-opioid receptor agonist, enadoline, increased feelings of depersonalization in a small sample of individuals with histories of substance abuse [112].”
From Treatment of dissociative identity disorder: leveraging neurobiology to optimize success (2024) · cites this paper as [112]
Citations
Cites
Opioid analgesics and antagonists
Reisine, T. (1996) · Medical Entomology and Zoology · Cited by 1,205
Martin, W. R., Sloan, J. W., Sapira, J. D., & Jasinski, D. R. (1971) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt1971122part1245 · Cited by 943
Psychotomimesis Mediated by κ Opiate Receptors
Pfeiffer, A., Brantl, V., Herz, A., & Emrich, H. M. (1986) · Science · doi:10.1126/science.3016896 · Cited by 857 · cited 3×
“These adverse effects have led some researchers to classify kappa agonists as psychotomimetics ( Pfeiffer et al. 1986 ) and have contributed to the failure of some of these agents in clinical trials.”
BackgroundResultInfluentialInteractions between Kappa Opioid Agonists and Cocaine: Preclinical Studies
Mello, N. K., & Negus, S. S. (2000) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2000.tb06678.x · Cited by 247
The reinforcing and subjective effects of morphine in post-addicts: a dose-response study.
Lamb, R. J., Preston, K. L., Schindler, C. W., Meisch, R. A., Davis, F., Katz, J. L., Henningfield, J. E., & Goldberg, S. R. (1991) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)20504-3 · Cited by 245 · cited 1×
“whereby morphine is perceived as dysphoric in drug-naive individuals but euphorigenic in experienced users ( Lamb et al. 1991; Zacny et al. 1994a).”
BackgroundFraser, H. F., Van Horn, G. D., Martin, W. R., Wolbach, A. B., & Isbell, H. (1961) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)26118-3 · Cited by 232
Assessment of the Abuse Potentiality of Morphinelike Drugs (Methods Used in Man)
Jasinski, D. R. (1977) · Drug Addiction I · doi:10.1007/978-3-642-66612-4_4 · Cited by 200
Hill, J. L., & Zacny, J. P. (2000) · Psychopharmacology · doi:10.1007/s002130000500 · Cited by 195 · cited 2×
“For example, human drug discrimination studies report that the subjective effects of butorphanol are more kappa-like than mu-like (Preston et al. 1989; Preston and Bigelow 1994; see Dykstra et al. 1997 for review) and a direct dosing study suggests that butorphanol can be readily differentiated from a pure mu agonist…”
BackgroundSelectivity of Ligands for Opioid Receptors
Corbett, A. D., Paterson, S. J., & Kosterlitz, H. W. (1993) · Handbook of Experimental Pharmacology · doi:10.1007/978-3-642-77460-7_26 · Cited by 184 · cited 1×
“Enadoline is a potent compound which binds with high affinity to kappa sites (Ki=0.11 nM) and is estimated to be 900- and 9000-fold more selective for kappa over mu and delta opiate receptors, respectively (Clark et al. 1988; Boyle et al. 1990; Corbett et al. 1993 ).”
BackgroundInfluentialDykstra, L. A., Gmerek, D. E., Winger, G., & Woods, J. H. (1987) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)39097-x · Cited by 168
Cited by
Structure of the human κ-opioid receptor in complex with JDTic
Wu, H., Wacker, D., Mileni, M., Katritch, V., Han, G. W., Vardy, E., Liu, W., Thompson, A. A., Huang, X.-P., Carroll, F. I., et al. (2012) · Nature · doi:10.1038/nature10939 · Cited by 879
Salvinorin A: A potent naturally occurring nonnitrogenous κ opioid selective agonist
Roth, B. L., Baner, K., Westkaemper, R., Siebert, D., Rice, K. C., Steinberg, S., Ernsberger, P., & Rothman, R. B. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.182234399 · Cited by 784
Reducing safety-related drug attrition: the use of in vitro pharmacological profiling
Bowes, J., Brown, A. J., Hamon, J., Jarolimek, W., Sridhar, A., Waldron, G., & Whitebread, S. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3845 · Cited by 748
Kozlowska, K., Walker, P., McLean, L., & Carrive, P. (2015) · Harvard Review of Psychiatry · doi:10.1097/hrp.0000000000000065 · Cited by 468
“Lanius (2014)(110) hypothesizes that symptoms of derealization and depersonalization during tonic immobility and other dissociative states may be mediated by kappa opioids—also known as dynorphins— because their activation has been documented in experiments of tonic immobility in animals and because they are known to…”
BackgroundCarlezon, W. A., Béguin, C., DiNieri, J. A., Baumann, M. H., Richards, M. R., Todtenkopf, M. S., Rothman, R. B., Ma, Z., Lee, D. Y.-W., & Cohen, B. M. (2006) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.105.092304 · Cited by 390
Dynorphin and the pathophysiology of drug addiction
Shippenberg, T. S., Zapata, A., & Chefer, V. I. (2007) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2007.06.011 · Cited by 387
“Furthermore, the dose-response curve for the aversive effects of KOPr agonists is shifted to the right in individuals with a prior history of polysubstance abuse or those suffering from chronic pain (Pande et al., 1996; Walsh et al., 2001).”
BackgroundBreaking barriers to novel analgesic drug development
Yekkirala, A. S., Roberson, D. P., Bean, B. P., & Woolf, C. J. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.87 · Cited by 364
Sex Differences in Opioid Analgesia: “From Mouse to Man”
Craft, R. M. (2003) · The Clinical Journal of Pain · doi:10.1097/00002508-200305000-00005 · Cited by 319
kappa-Opioid receptor signaling and brain reward function
Bruijnzeel, A. W. (2009) · Brain Research Reviews · doi:10.1016/j.brainresrev.2009.09.008 · Cited by 214
Watt, D. F., & Panksepp, J. (2009) · Neuropsychoanalysis · doi:10.1080/15294145.2009.10773593 · Cited by 208
Millière, R. (2017) · Frontiers in Human Neuroscience · doi:10.3389/fnhum.2017.00245 · Cited by 206
“However, there is evidence that salvinorin-A and other selective KOR agonists such as enadoline can induce ego dissolution experiences (Pfeiffer et al., 1986; Walsh et al., 2001; González et al., 2006; Johnson et al., 2011).”
BackgroundThe predictive validity of the rat self-administration model for abuse liability
O’Connor, E. C., Chapman, K., Butler, P., & Mead, A. N. (2011) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2010.10.012 · Cited by 203
Profiling 976 ToxCast Chemicals across 331 Enzymatic and Receptor Signaling Assays
Sipes, N. S., Martin, M. T., Kothiya, P., Reif, D. M., Judson, R. S., Richard, A. M., Houck, K. A., Dix, D. J., Kavlock, R. J., & Knudsen, T. B. (2013) · Chemical Research in Toxicology · doi:10.1021/tx400021f · Cited by 203
Models of psychedelic drug action: modulation of cortical-subcortical circuits
Doss, M. K., Madden, M. B., Gaddis, A., Nebel, M. B., Griffiths, R. R., Mathur, B. N., & Barrett, F. S. (2022) · Brain · doi:10.1093/brain/awab406 · Cited by 199
Orexin/hypocretin role in reward: implications for opioid and other addictions
Baimel, C., Bartlett, S. E., Chiou, L., Lawrence, A. J., Muschamp, J. W., Patkar, O., Tung, L., & Borgland, S. L. (2015) · British Journal of Pharmacology · doi:10.1111/bph.12639 · Cited by 179
“, 1993), and produces anxiety and dysphoria in humans (Pfeiffer et al., 1986; Walsh et al., 2001); and the aversive effects of ‘stress peptides’ like corticotropin-releasing factor (CRF) exert their dysphoric effects via dynorphin and κ-opioid receptor activation (Land et al.”
BackgroundPattern of use and subjective effects of Salvia divinorum among recreational users
González, D., Riba, J., Bouso, J. C., Gómez-Jarabo, G., & Barbanoj, M. J. (2006) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2006.04.001 · Cited by 163
Opioid Receptors in Immune and Glial Cells—Implications for Pain Control
Machelska, H., & Celik, M. Ö. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00300 · Cited by 159
Carlezon, W. A., & Krystal, A. D. (2016) · Depression and Anxiety · doi:10.1002/da.22500 · Cited by 158
“First, administration of KOR agonists to people produces dysphoric and depressive effects.[17, 18] Second, microinjections of KOR agonists into the NAc produce conditioned place aversions resembling those seen with intermediate doses of cocaine in rats overexpressing CREB in the NAc.”
The dynorphin/κ-opioid receptor system and its role in psychiatric disorders
Tejeda, H. A., Shippenberg, T. S., & Henriksson, R. (2011) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-011-0844-x · Cited by 179
“Intramuscular administration of enadoline, a synthetic KOR agonist, produces effects perceived as ‘‘bad’’ in humans and psychotomimetic effects at higher doses [230].”
BackgroundKappa-opioid ligands in the study and treatment of mood disorders
Carlezon, W. A., Béguin, C., Knoll, A. T., & Cohen, B. M. (2009) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2009.05.008 · Cited by 156
“In clinical studies of substance abusers, the KOR agonist enadoline reduces some of the effects of cocaine, but also caused sedation, depersonalization, visual distortions, confusion, and (at high doses) paranoia (Walsh et al., 2001a, 2001b).”
BackgroundEndogenous opioids and nonsuicidal self-injury: A mechanism of affect regulation
Bresin, K., & Gordon, K. H. (2013) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2013.01.020 · Cited by 189
Buprenorphine versus methadone for opioid dependence: predictor variables for treatment outcome
Gerra, G., Borella, F., Zaimovic, A., Moi, G., Bussandri, M., Bubici, C., & Bertacca, S. (2004) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2003.11.017 · Cited by 161
“…have been reported to increase dysphoria, confusion, sedation and to produce feelings of depersonalization in humans (Greenwald and Stitzer, 1998; Walsh et al., 2001), supporting the hypothesis that BUP may counteract in depressed subjects the emotional and perceptual effects of -receptors…”
Johnson, M. W., MacLean, K. A., Reissig, C. J., Prisinzano, T. E., & Griffiths, R. R. (2011) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2010.11.005 · Cited by 136
“Because kappa opioid agonists, including salvinorin A, have been reported to induce dysphoric effects (Walsh et al., 2001; González et al., 2006), participants were asked to complete retrospective ratings of “drug liking” and “drug disliking” (2 questions; 0= neutral or no effect, 1=like/dislike but not very much, 2=l…”
InfluentialBorderline personality disorder: a dysregulation of the endogenous opioid system?
Bandelow, B., Schmahl, C., Falkai, P., & Wedekind, D. (2010) · Psychological Review · doi:10.1037/a0018095 · Cited by 135
Tejeda, H. A., Counotte, D. S., Oh, E. J., Ramamoorthy, S., Schultz‐Kuszak, K., Bäckman, C. M., Chefer, V., O’Donnell, P., & Shippenberg, T. S. (2013) · Neuropsychopharmacology · doi:10.1038/npp.2013.76 · Cited by 143
Presynaptic Opioid and Nicotinic Receptor Modulation of Dopamine Overflow in the Nucleus Accumbens
Britt, J. P., & McGehee, D. S. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.4275-07.2008 · Cited by 130
“Both rats and humans find systemic administration of -opioids aversive and, in the rat, there is a corresponding decrease in extracellular DA concentrations in the NAc (Pfeiffer et al., 1986; Donzanti et al., 1992; Thompson et al., 2000; Walsh et al., 2001).”
BackgroundRecent Advances in the Biological Study of Personality Disorders
New, A. S., Goodman, M. S., Triebwasser, J., & Siever, L. J. (2008) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2008.03.011 · Cited by 138
Ranganathan, M., Schnakenberg, A., Skosnik, P. D., Cohen, B. M., Pittman, B., Sewell, R. A., & D'Souza, D. C. (2012) · Biological Psychiatry · doi:10.1016/j.biopsych.2012.06.012 · Cited by 124
The Kappa Opioid Receptor: A Promising Therapeutic Target for Multiple Pathologies
Dalefield, M. L., Scouller, B., Bibi, R., & Kivell, B. M. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.837671 · Cited by 145
Kappa opioids and the modulation of pain
Kivell, B. M., & Prisinzano, T. E. (2010) · Psychopharmacology · doi:10.1007/s00213-010-1819-6 · Cited by 136
Tejeda, H. A., & Bonci, A. (2018) · Brain Research · doi:10.1016/j.brainres.2018.09.023 · Cited by 123
Targeting Itch with Ligands Selective for κ Opioid Receptors
Cowan, A., Kehner, G. B., & Inan, S. (2015) · Handbook of experimental pharmacology · doi:10.1007/978-3-662-44605-8_16 · Cited by 117
Naltrexone and buprenorphine combination in the treatment of opioid dependence
Gerra, G., Fantoma, A., & Zaimovic, A. (2006) · Journal of Psychopharmacology · doi:10.1177/0269881106060835 · Cited by 106
Arendt‐Nielsen, L., Olesen, A. E., Staahl, C., Menzaghi, F., Kell, S. H., Wong, G. Y., & Drewes, A. M. (2009) · Anesthesiology · doi:10.1097/aln.0b013e3181af6356 · Cited by 113
Butelman, E. R., Harris, T. J., & Kreek, M. J. (2004) · Psychopharmacology · doi:10.1007/s00213-003-1638-0 · Cited by 108
“Synthetic k-agonists administered systemically to humans are known to produce a variety of dose-dependent and reversible subjective/interoceptive effects, including sedation, dysphoria and “psychotomimetic” effects (Pfeiffer et al. 1986; Ur et al. 1997; Walsh et al. 2001).”
Mula, M., Pini, S., & Cassano, G. B. (2007) · Journal of Affective Disorders · doi:10.1016/j.jad.2006.08.025 · Cited by 100
McDonald, J., & Lambert, D. G. (2005) · Continuing Education in Anaesthesia Critical Care & Pain · doi:10.1093/bjaceaccp/mki004 · Cited by 104
Understanding and treating depersonalisation disorder
Medford, N., Sierra, M., Baker, D., & David, A. S. (2005) · Advances in Psychiatric Treatment · doi:10.1192/apt.11.2.92 · Cited by 93
“…selective kappa opioid receptor agonist https://doi.org/10.1192/apt.11.2.92 Published online by Cambridge University Press Medford et al enadoline has been found to induce depersonal-isation, although this was only one of numerous reported physical and psychological effects (Walsh et al , 2001).”
InfluentialThe Kappa-Opioid Agonist U69,593 Blocks Cocaine-Induced Enhancement of Brain Stimulation Reward
Tomasiewicz, H. C., Todtenkopf, M. S., Chartoff, E. H., Cohen, B. M., & Carlezon, W. A. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2008.05.029 · Cited by 90
“Still other studies demonstrate that KOR agonists reduce symptoms of Tourette’s Syndrome (43,44).”
BackgroundMitchell, J., Liang, M. T., & Fields, H. L. (2005) · Psychopharmacology · doi:10.1007/s00213-005-0067-7 · Cited by 96
“Additionally, KOR agonists induce dysphoria in humans (O’Brien et al. 1996; O’Malley 1996; Walsh et al. 2001) and cause conditioned place aversion in animals (Shippenberg and Herz 1986).”
BackgroundBuprenorphine treatment outcome in dually diagnosed heroin dependent patients: A retrospective study
Gerra, G., Leonardi, C., D'Amore, A., Strepparola, G., Fagetti, R., Assi, C., Zaimovic, A., & Lucchini, A. (2006) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2005.10.007 · Cited by 88
“attributable to the specific pharmacological profile of the drug, being BUP a partial mu agonist/kappa antagonist: in fact, kappa receptors agonist, such as butorphanol and enadoline have been reported to increase dysphoria, confusion, sedation and to produce feelings of depersonalisation in humans (Greenwald and Stit…”
BackgroundResultButorphanol: Effects of a Prototypical Agonist-Antagonist Analgesic on κ-Opioid Receptors
Commiskey, S., Fan, L., Ho, I. K., & Rockhold, R. W. (2005) · Journal of Pharmacological Sciences · doi:10.1254/jphs.crj05001x · Cited by 87
Antinociceptive Effects of Hydromorphone, Butorphanol, or the Combination in Cats
Lascelles, B. D. X., & Robertson, S. A. (2004) · Journal of Veterinary Internal Medicine · doi:10.1111/j.1939-1676.2004.tb00159.x · Cited by 87
Munro, T. A., & Rizzacasa, M. A. (2003) · Journal of Natural Products · doi:10.1021/np0205699 · Cited by 83
An Open Trial of Naltrexone in the Treatment of Depersonalization Disorder
Simeon, D., & Knutelska, M. (2005) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000162803.61700.4f · Cited by 80
“The k opioid system is also implicated in dissociation: the k opioid agonist enadoline has been shown to induce a potent ‘‘clean’’ depersonalization-like syndrome in healthy subjects compared to placebo, with perceptual disturbances and a sense of detachment.(11) Along these lines, opiate antagonists have been reporte…”
BackgroundUse patterns and self-reported effects of Salvia divinorum: An internet-based survey
Baggott, M. J., Erowid, E., Erowid, F., Galloway, G. P., & Mendelson, J. E. (2010) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2010.05.003 · Cited by 84
Maqueda, A. E., Valle, M., Addy, P. H., Antonijoan, R. M., Puntes, M., Coimbra, J., Ballester, M. R., Garrido, M., González, M., Claramunt, J., et al. (2015) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyv065 · Cited by 73
“Older nitrogenated KOR agonists such as enadoline are known to induce unpleasant reactions, and modifications in perception usually appear at high doses (Walsh et al., 2001).”
BackgroundMu/kappa opioid interactions in rhesus monkeys: Implications for analgesia and abuse liability.
Negus, S. S., Schrode, K. M., & Stevenson, G. W. (2008) · Experimental and Clinical Psychopharmacology · doi:10.1037/a0013088 · Cited by 75
“It is wellestablished that selective kappa agonists produce psychotomimetic effects in humans (Pfeiffer et al., 1986; Walsh et al., 2001), and attempts to develop selective kappa agonists as analgesics have foundered in part because patients find these psychotomimetic effects to be aversive.”
Synthesis and in vitro pharmacological evaluation of salvinorin A analogues modified at C(2)
Béguin, C., Richards, M. R., Wang, Y., Chen, Y., Liu‐Chen, L., Ma, Z., Lee, D. Y. W., Carlezon, W. A., & Cohen, B. M. (2005) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2005.03.113 · Cited by 72
Frankel, P. S., Alburges, M. E., Bush, L. G., Hanson, G. R., & Kish, S. J. (2008) · Neuropharmacology · doi:10.1016/j.neuropharm.2008.04.019 · Cited by 79
“In human clinical studies κ-opioid agonist administration produces a variety of subjective effects including dysphoria and perceptual disturbances (Walsh et al., 2001).”
BackgroundBowen, C. A., Negus, S. S., Zong, R., Neumeyer, J. L., Bidlack, J. M., & Mello, N. K. (2002) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300105 · Cited by 77
“For example, in normal men, enadoline (15 or 25 mg) produced a number of adverse side effects (Reece et al, 1994), whereas in opioid abusers up to 80 mg of enadoline produced dysphoria and sedative effects but no significant sensory disturbances or other side effects (Walsh et al, 2001).”
BackgroundSalvinorin A Analogs and Other Kappa-Opioid Receptor Compounds as Treatments for Cocaine Abuse
Kivell, B. M., Ewald, A. W. M., & Prisinzano, T. E. (2014) · Advances in pharmacology · doi:10.1016/b978-0-12-420118-7.00012-3 · Cited by 74
Walsh, S. L., Geter-Douglas, B., Strain, E. C., & Bigelow, G. E. (2001) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)29312-5 · Cited by 68
“Butorphanol, thought to act as both a partial - and partial -agonist (Leander, 1983; Dykstra, 1990; Vivian et al., 1999), produces an acute subjective effects profile comprised of both prototypic - and -opioid effects (Jasinski et al., 1976; Preston and Bigelow, 1994; Walsh et al., 2001).”
Self-citationRoles of Nucleus Accumbens CREB and Dynorphin in Dysregulation of Motivation
Muschamp, J. W., & Carlezon, W. A. (2013) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a012005 · Cited by 70
“Given systemically, KOR agonists are aversive in humans, producing dysphoria and anxiety (Pfeiffer et al. 1986; Walsh et al. 2001).”
BackgroundComer, S. D., Zacny, J. P., Dworkin, R. H., Turk, D. C., Bigelow, G. E., Foltin, R. W., Jasinski, D. R., Sellers, E. M., Adams, E. H., Balster, R. L., et al. (2012) · Pain · doi:10.1016/j.pain.2012.07.035 · Cited by 73
“, ‘‘feel bad’’) and no evidence of liking or good effects from the drug [49,65].”
Self-citationAcute and post-acute behavioral and psychological effects of salvinorin A in humans
Addy, P. H. (2011) · Psychopharmacology · doi:10.1007/s00213-011-2470-6 · Cited by 74
“resulted in hallucinations (Walsh et al. 2001).”
Salvinorin A: A novel and highly selective κ-opioid receptor agonist
Yan, F., & Roth, B. L. (2004) · Life Sciences · doi:10.1016/j.lfs.2004.07.008 · Cited by 78
“…KOR agonists might have limited usefulness in humans because of psychotomimetic and dysphoric actions (Pfeiffer et al., 1986; Rimoy et al., 1994; Walsh et al., 2001) although it has been unclear to what extent the dpsychotomimeticT or dysphoric actions of KOR agonists are mediated by KOR or…”
BackgroundClark, S. D., & Abi‐Dargham, A. (2019) · Biological Psychiatry · doi:10.1016/j.biopsych.2019.05.012 · Cited by 74
Lee, D. Y. W., Ma, Z., Liu‐Chen, L., Wang, Y., Chen, Y., Carlezon, W. A., & Cohen, B. M. (2005) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2005.05.054 · Cited by 75
Effects of Butorphanol on Morphine-induced Itch and Analgesia in Primates
Lee, H., Naughton, N. N., Woods, J. H., & Ko, M. (2007) · Anesthesiology · doi:10.1097/01.anes.0000278876.20263.a7 · Cited by 65
Buprenorphine Pharmacodynamics and Pharmacokinetics
WALSH, S. L., & Middleton, L. S. (2013) · Springer eBooks · doi:10.1007/978-1-4614-6974-2_12 · Cited by 65
“For example, as kappa agonists are known to produce signifi cant dysphoric effects [ 6 , 7 ], studies have explored the possibility that buprenorphine, with its kappa antagonist actions, may produce euphoria as a secondary effect, thereby acting as an antidepressant to enhance mood.”
BackgroundSelf-citationSynthesis and in vitro pharmacological studies of new C(2) modified salvinorin A analogues
Lee, D. Y. W., Karnati, V. V. R., He, M., Liu‐Chen, L., Kondaveti, L., Ma, Z., Wang, Y., Chen, Y., Béguin, C., Carlezon, W. A., et al. (2005) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2005.05.048 · Cited by 66
Depersonalization disorder: pharmacological approaches
Sierra, M. (2008) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.8.1.19 · Cited by 62
Grimwood, S., Lu, Y., Schmidt, A. W., Vanase-Frawley, M. A., Sawant‐Basak, A., Miller, E. L., McLean, S., Freeman, J., Wong, S., McLaughlin, J. P., et al. (2011) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.111.185108 · Cited by 64
“KOR agonists, such as butorphanol and enadoline, have been reported to increase dysphoria, confusion, and sedation and produce feelings of depersonalization in humans (Greenwald and Stitzer, 1998; Walsh et al., 2001), whereas the naturally occurring selective KOR agonist salvinorin A induces hallucinations (Roth et al.”
Horton, D. B., Potter, D. M., & Mead, A. N. (2013) · Behavioural Pharmacology · doi:10.1097/fbp.0b013e3283644d2e · Cited by 61
Genetic association analyses of PDYN polymorphisms with heroin and cocaine addiction
Clarke, T. ‐., Ambrose‐Lanci, L., Ferraro, T. N., Berrettini, W. H., Kampman, K. M., Dackis, C. A., Pettinati, H. M., O’Brien, C. P., Oslin, D. W., & Lohoff, F. W. (2012) · Genes, Brain and Behavior · doi:10.1111/j.1601-183x.2012.00785.x · Cited by 55
“2005) and dysphoria/confusion in humans (Shippenberg et al. 2007; Walsh et al. 2001).”
BackgroundOrvinols with Mixed Kappa/Mu Opioid Receptor Agonist Activity
Greedy, B. M., Bradbury, F. A., THOMAS, M. P., Grivas, K., Cami‐Kobeci, G., Archambeau, A., Bosse, K. E., Clark, M. J., Aceto, M. D. G., Lewis, J. W., et al. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm301543e · Cited by 54
The neuropsychophysiology of tingling
Tihanyi, B. T., Ferentzi, E., Beißner, F., & Köteles, F. G. (2017) · Consciousness and Cognition · doi:10.1016/j.concog.2017.10.015 · Cited by 60
Béguin, C., Potter, D. N., DiNieri, J. A., Munro, T. A., Richards, M. R., Paine, T. A., Berry, L., Zhao, Z., Roth, B. L., Xu, W., et al. (2007) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.107.129023 · Cited by 54
“…2003; Todtenkopf et al., 2004; Cohen and Murphy, 2007), responses to drugs of abuse (Shippenberg and Rea, 1997), sense of space and time (Pfeiffer et al., 1986; Walsh et al., 2001; Dortch-Carnes and Potter, 2005), and pain perception (Barber and Gottschlich, 1997; Dortch-Carnes and Potter, 2005).”
BackgroundSchroeder, C. A., & Smith, L. J. (2011) · Europe PMC (PubMed Central) · Cited by 50
Neuraxial Opioid-Induced Itch and Its Pharmacological Antagonism
Ko, M. (2015) · Handbook of experimental pharmacology · doi:10.1007/978-3-662-44605-8_17 · Cited by 50
“For example, MOP agonists produce euphoria, whereas KOP agonists produce dysphoria (Kumor et al. 1986; Walsh et al. 2001); MOP agonists produce antidiuretic effects, while KOP agonists produce diuresis (Peters et al. 1987; Weiskopf et al. 1987).”
BackgroundHeal, D. J., Gosden, J., & Smith, S. L. (2018) · Neuropharmacology · doi:10.1016/j.neuropharm.2018.01.049 · Cited by 49
“Enadoline was compared with butorphanol and hydromorphone in drug-experienced volunteers (Walsh et al., 2001a) and its influence on the pharmacodynamics and selfadministration of cocaine have been investigated (Walsh et al., 2001b).”
BackgroundMethodGENETIC STUDY: Prodynorphin gene promoter repeat associated with cocaine/alcohol codependence
Williams, T. J., LaForge, K. S., Gordon, D., Bart, G., Kellogg, S., Ott, J., & Kreek, M. J. (2007) · Addiction Biology · doi:10.1111/j.1369-1600.2007.00069.x · Cited by 48
Pain-relieving effects of processed Aconiti tuber in CCI-neuropathic rats
Xu, H., Arita, H., Hayashida, M., Zhang, L., Sekiyama, H., & Hanaoka, K. (2005) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2005.08.050 · Cited by 47
Muschamp, J. W., Nemeth, C. L., Robison, A. J., Nestler, E. J., & Carlezon, W. A. (2012) · Biological Psychiatry · doi:10.1016/j.biopsych.2011.08.011 · Cited by 46
Kivell, B. M., Paton, K. F., Kumar, N., Morani, A. S., Culverhouse, A., Shepherd, A. L., Welsh, S. A., Biggerstaff, A., Crowley, R. S., & Prisinzano, T. E. (2018) · Molecules · doi:10.3390/molecules23102602 · Cited by 48
“However, the side-effects of traditional KOPr agonists, such as depression [16], dysphoria [17,18], sedation [19], and aversion [20,21] have limited the therapeutic development of these agents.”
BackgroundKarpyak, V. M., Winham, S. J., Preuss, U. W., Zill, P., Cunningham, J. M., Walker, D. L., Lewis, K. A., Geske, J. R., Colby, C. L., Abulseoud, O. A., et al. (2013) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145712001137 · Cited by 47
“Evidence also demonstrates that the brain dynorphin/ KOR system plays a role in the motivational aspects of stress by mediating pro-depressive-like states that involve elements of anhedonia, dysphoria and aversion in humans and laboratory animals (Knoll et al. 2007; Todtenkopf et al. 2004; Wadenberg, 2003 ; Walsh et a…”
Backgroundβ-Phenylethylamines and the isoquinoline alkaloids
Bentley, K. W. (2003) · Natural Product Reports · doi:10.1039/b111626f · Cited by 50
Aldrich, J. V., Senadheera, S. N., Ross, N. C., Ganno, M. L., Eans, S. O., & McLaughlin, J. P. (2013) · Journal of Natural Products · doi:10.1021/np300697k · Cited by 47
Bipolar disorder: candidate drug targets
Zarate, C. A., & Manji, H. K. (2008) · Mount Sinai Journal of Medicine A Journal of Translational and Personalized Medicine · doi:10.1002/msj.20042 · Cited by 45
D’Addario, C., Palazzo, M. C., Benatti, B., Grancini, B. M., Pucci, M., Francesco, A. D., Camuri, G., Galimberti, D., Fenoglio, C., Scarpini, E. A., et al. (2017) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2017.08.011 · Cited by 46
“However, the psychotomimetic and dysphoric effects of KOP agonists to the central nervous system are also well-documented, clearly limiting their use for human therapy (Rimoy et al., 1994; Walsh et al., 2001).”
BackgroundOpioid peptide-derived analgesics
Schiller, P. W. (2005) · The AAPS Journal · doi:10.1208/aapsj070356 · Cited by 42
Kappa Opioid Receptor Activation Disrupts Prepulse Inhibition of the Acoustic Startle in Rats
Bortolato, M., Aru, G. N., Frau, R., Orrù, M., Fà, M., Manunta, M., Puddu, M., Mereu, G., & Gessa, G. L. (2005) · Biological Psychiatry · doi:10.1016/j.biopsych.2005.02.030 · Cited by 41
The Kappa‐Opiate Receptor Impacts the Pathophysiology and Behavior of Substance Use
Mysels, D. J., & Sullivan, M. A. (2009) · American Journal on Addictions · doi:10.1080/10550490902925862 · Cited by 38
“44 In a study of rats, the kappa agonist U50,488 dose-dependently reduced prepulse inhibition to auditory gating, a hypothesized model for psychotic thought disorder.”
BackgroundEndogenous opiates and behavior: 2001
Bodnar, R. J., & Hadjimarkou, M. M. (2002) · Peptides · doi:10.1016/s0196-9781(02)00306-6 · Cited by 45
Mendelson, J. E., Coyle, J. R., Lopez, J. C., Baggott, M. J., Flower, K., Everhart, E. T., Munro, T. A., Galloway, G. P., & Cohen, B. M. (2011) · Psychopharmacology · doi:10.1007/s00213-010-2103-5 · Cited by 38
“…lopez.juan.c@gmail.com E. T. Everhart Department of Psychiatry, UCSF, San Francisco, CA, USA T. A. Munro :B. M. Cohen Department of Psychiatry, Harvard Medical School, Cambridge, MA, USA T. A. Munro :B. M. Cohen McLean Hospital, Belmont, MA, USA hallucinations, and dissociation (Walsh et al. 2001).”
BackgroundPossible role of a dysregulation of the endogenous opioid system in antisocial personality disorder
Bandelow, B., & Wedekind, D. (2015) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.2497 · Cited by 41
“In contrast to the positive effects of endorphins, stimulation of κ-opioid receptors, for example, by dynorphins, can induce dysphoria (Walsh et al., 2001).”
ResultAkaberi, M., Iranshahi, M., & Mehri, S. (2016) · Phytotherapy Research · doi:10.1002/ptr.5599 · Cited by 41
“…have shown that peripherally active KOR agonists have few side-effects and a limited potential for abuse (DeHaven-Hudkins and Dolle, 2004), whereas centrally acting KOR agonists may have psychotomimetic and dysphoric effects in humans (Pfeiffer et al., 1986; Rimoy et al., 1994; Walsh et al., 2001).”
BackgroundMorani, A. S., Schenk, S., Prisinzano, T. E., & Kivell, B. M. (2012) · Behavioural Pharmacology · doi:10.1097/fbp.0b013e3283512c1e · Cited by 33
“However, adverse effects such as sedation, aversion, and depression have prevented their clinical development (Walsh et al., 2001).”
InfluentialSalvia divinorum use and phenomenology: results from an online survey
Sumnall, H. R., Measham, F. C., Brandt, S. D., & Cole, J. C. (2010) · Journal of Psychopharmacology · doi:10.1177/0269881110385596 · Cited by 44
“divinorum use (Singh, 2007), and clinical administration of k-opioid receptor agonists are known to produce psychotomimesis in humans (Dykstra et al., 1997; Pfeiffer et al., 1986; Walsh et al., 2001).”
BackgroundMangel, A. W., & Hicks (2012) · Clinical and Experimental Gastroenterology · doi:10.2147/ceg.s23274 · Cited by 39
“25 In the study of IBS, low levels of asimadoline are used such that these side effects do not occur.”
Viscusi, E. R., Torjman, M. C., Munera, C. L., Stauffer, J. W., Setnik, B., & Bagal, S. (2021) · Clinical and Translational Science · doi:10.1111/cts.13042 · Cited by 36
The effects of pentazocine, a kappa agonist, in patients with mania
Cohen, B. M., & Murphy, B. L. (2007) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145707008073 · Cited by 35
“These effects are largely seen at high doses (Walsh et al., 2001) or under circumstances where psychotomimetic effects are sought for spiritual or recreational purposes (Gonzalez et al., 2006).”
BackgroundInfluentialEvaluation of Biased and Balanced Salvinorin A Analogs in Preclinical Models of Pain
Paton, K. F., Biggerstaff, A., Kaska, S., Crowley, R. S., Flamme, A. C. L., Prisinzano, T. E., & Kivell, B. M. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.00765 · Cited by 34
Reutens, S. G., Nielsen, O., & Sachdev, P. S. (2010) · Current Opinion in Psychiatry · doi:10.1097/yco.0b013e3283387ab4 · Cited by 37
Synthesis and in vitro pharmacological studies of C(4) modified salvinorin A analogues
Lee, D. Y. W., He, M., Kondaveti, L., Liu‐Chen, L., Ma, Z., Wang, Y., Chen, Y., Li, J.-G., Béguin, C., Carlezon, W. A., et al. (2005) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2005.06.092 · Cited by 38
Levy-Cooperman, N., McIntyre, G., Bonifácio, L., McDonnell, M., Davenport, J., Covington, P., Dove, L. S., & Sellers, E. M. (2016) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.116.236547 · Cited by 27
Bertea, C. M., Luciano, P., Bossi, S., Leoni, F., Baiocchi, C., Medana, C., Azzolin, C. M. M., Temporale, G., Lombardozzi, M. A., & Maffei, M. E. (2006) · Phytochemistry · doi:10.1016/j.phytochem.2005.12.006 · Cited by 34
“Synthetic j-agonists administered systemically to humans are known to produce a variety of dose-dependent and reversible subjective/interoceptive effects, including sedation, dysphoria and ‘‘psychotomimetic’’ effects (Pfeiffer et al., 1986; Ur et al., 1997; Walsh et al., 2001).”
BackgroundMaqueda, A. E., Valle, M., Addy, P. H., Antonijoan, R. M., Puntes, M., Coimbra, J., Ballester, M. R., Garrido, M., González, M. J., Claramunt, J., et al. (2016) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyw016 · Cited by 33
“Additionally, in contrast with these nitrogenated compounds, salvinorin-A displays perception-modifying rather than somato-dysphoric effects (Walsh et al., 2001), although salvinorin-A has not been compared directly with synthetic kappa agonists within one study.”
BackgroundEwald, A. W. M., Bösch, P., Culverhouse, A., Crowley, R. S., Neuenswander, B., Prisinzano, T. E., & Kivell, B. M. (2017) · Psychopharmacology · doi:10.1007/s00213-017-4637-2 · Cited by 35
“…arylacetamide agonists such as U50,488 and U69,593 also causes side effects that include sedation (Gallantine and Meert 2008), aversion (Land et al. 2009), anxiety (Gillett et al. 2013) and depression (Mague et al. 2003), effects that have limited their use clinically (Walsh et al. 2001a,b).”
Background
Metadata
- Authors
- Walsh, S., Strain, E., Abreu, M., & Bigelow, G.
- Affiliations
- Johns Hopkins University (US)
- AstraZeneca (United States) (US)
- Venue
- Psychopharmacology
- Published
- 2001-09-01
- Volume
- 157
- Issue
- 2
- Pages
- 151-162
- ISSN
- 0033-3158 (ISSN-L)
- 1432-2072
- OpenAlex
- W2148208755
- Cited by
- 258
- References
- 51
- Citations by year
- 2026: 7 · 2025: 11 · 2024: 6 · 2023: 5 · 2022: 6 · 2021: 19 · 2020: 9 · 2019: 5 · 2018: 6 · 2017: 7 · 2016: 15 · 2015: 14 · 2014: 6 · 2013: 15 · 2012: 10
- FWCI
- 2.46
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Psychopharmacology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- U.S. Public Health Service
- National Institute on Drug Abuse (K05DA000050, K05 DA00050, T32-DA07209, R01 DA10753, R01DA010753, T32DA007209)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuropeptides and Animal Physiology
- Health Sciences › Medicine › Anesthesiology and Pain Medicine › Pain Management and Opioid Use
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Opioid Use Disorder Treatment
- Keywords
- kappa opioid receptor agonists, butorphanol, hydromorphone, opioid pharmacodynamics, sedation, psychotomimetic effects, respiratory depression, polysubstance abuse, opioid analgesics, drug safety
- MeSH terms
- Adult, Analgesics, Opioid, Analysis of Variance, Benzofurans, Butorphanol, Hydromorphone, Dose-Response Relationship, Drug, Double-Blind Method, Female, Heroin Dependence, Humans, Male, Middle Aged, Pilot Projects, Pyrrolidines, Receptors, Opioid, kappa, Cross-Over Studies, Neuroprotective Agents
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.